Get started
Author

Diels van den Dobbelsteen

Observed name: Diels Van Den Dobbelsteen
OpenAlex ID: A5066489599
The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers
2015 · Miranda M.C. van der Lee, Patrick G. Groothuis, et al. · Molecular Cancer Therapeutics · 202
Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform
2014 · Wim Dokter, Ruud Ubink, et al. · Molecular Cancer Therapeutics · 166
Sugammadex is cleared rapidly and primarily unchanged via renal excretion
2011 · Pierre Peeters, Paul Passier, et al. · Biopharmaceutics & Drug Disposition · 59
BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells
2023 · Mary J van Helden, Seline A Zwarthoff, et al. · Journal for ImmunoTherapy of Cancer · 23
PDF
Role of thiol homeostasis and adenine nucleotide metabolism in the protective effects of fructose in quinone-induced cytotoxicity in rat hepatocytes
1994 · Corike Toxopeus, Ineke van Holsteijn, et al. · Biochemical Pharmacology · 6
Abstract 925: Introduction to the preclinical profile of SYD1875, a novel site-specifically conjugated duocarmycin-based 5T4-targeting antibody-drug conjugate
2021 · Patrick Groothuis, Danielle Jacobs, et al. · Cancer Research · 5
Abstract 2651: Impressive efficacy and safety profile of a novel generation duocarmycin-based HER2-targeting ADC
2014 · Willem Dokter, Ruud Ubink, et al. · Cancer Research · 2
Abstract 4329: Novel HER2 targeting antibody-drug conjugates based on DNA-interacting duocarmycin and an unique linker technology with great potential in breast cancer and NSCLC.
2013 · Wim Dokter, Patrick Beusker, et al. · Cancer Research · 2
Abstract 6921: Phosphonate-antibody-drug conjugates, a novel immunostimulatory class of ADCs driving inside-out activation of Vγ9Vδ2 T cells leading to selective tumor cell killing
2026 · Mary J. van Helden, Genny Filliciotto, et al. · Cancer Research · 1
Abstract 5360: The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers
2015 · Willem Dokter, Miranda van der Lee, et al. · Cancer Research · 1
Strategies in industrial genotoxicity testing of drugs
2007 · Frederique van Acker, Harrie Joosten, et al. · Toxicology Letters · 1
954 Phosphonate-antibody-drug conjugates: a novel immunostimulatory class of ADCs driving inside-out activation of Vγ9Vδ2 T cells leading to selective tumor cell killing
2025 · Mary JVan Helden, Genny Filiciotto, et al. · Journal for ImmunoTherapy of Cancer
PDF
1160 Phosphonate-antibody-drug conjugates: a novel immunostimulatory class of ADCs driving inside-out activation of Vγ9Vδ2 T cells leading to selective tumor cell killing
2023 · Mary J van Helden, Ronald C Elgersma, et al. · Journal for ImmunoTherapy of Cancer
PDF
Abstract 2934: BYON4228, an antagonistic SIRPα mAb with a unique and favorable preclinical profile compared to three comparator SIRPα mAbs
2023 · Mary van Helden, Seline Zwarthoff, et al. · Cancer Research
Supplementary Materials and Methods from Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform
2023 · Wim Dokter, Ruud Ubink, et al.
Supplementary Tables 1 - 5 and Figures 1 - 3 from Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform
2023 · Wim Dokter, Ruud Ubink, et al.
Supplementary Tables 1 through 3 and Supplementary Figures 1 through 6 from The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers
2023 · Miranda M.C. van der Lee, Patrick G. Groothuis, et al.
Supplementary Tables 1 through 3 and Supplementary Figures 1 through 6 from The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers
2023 · Miranda M.C. van der Lee, Patrick G. Groothuis, et al.
Data from Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform
2023 · Wim Dokter, Ruud Ubink, et al.
Data from The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers
2023 · Miranda M.C. van der Lee, Patrick G. Groothuis, et al.
Data from The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers
2023 · Miranda M.C. van der Lee, Patrick G. Groothuis, et al.
Abstract 5589: BYON4228 is a pan-allelic SIRPα antibody that potentiates killing of antibody-opsonized tumor cells and lacks binding to T cells
2022 · Mary van Helden, Seline Zwarthoff, et al. · Cancer Research
Role of glutathione in the redox regulation of apoptotic cell death
1998 · Sten Orrenius, Diels van den Dobbelsteen, et al. · Pathophysiology
Works count: 23
Citation count: 468
H-index: 5
I10-index: 4
Year
Topic
Type